Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies

Main Article Content

Melinda Gooderham
Javier Alonso-Llamazares
Jerry Bagel
John Browning
Zoe Draelos
Kimberly Grande
Adelaide Herbert
Wei Jing Loo
Chih-ho Hong
Mark Lebwohl
Walter Nahm
Kim Papp
David Pariser
Jennifer Soung
Linda Stein Gold
Irina Turchin
Amy Feng
Patrick Burnett
Robert Higham
David Berk

Keywords

roflumilast, psoriasis, itch, DERMIS phase 3 trial

Abstract

N/A

References

1. Elewski B, et al. J Eur Acad Dermatol Venereol 2019;33:1465-1476.

2. Globe D, et al. Health Qual Life Outcomes 2009;7:62.

3. Lebwohl MG, et al. N Engl J Med 2020;383:229-239.

4. Lebwohl MG, et al. 2021 European Academy of Dermatology and Venereology Spring Symposium, Sept 29–Oct 2, 2021.

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 12 > >>